Cystic Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 25 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies.
Forgione Federico et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42373575/
- 2.
Early and mature
Jean-Pierre Vincent et al. — Biofilm (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42358622/
- 3.
A feasibility pilot trial to deliver a virtual intervention for promoting daily self-management in adolescents and young adults with cystic fibrosis: A brief report of tele-coach outcomes.
Lindwall Jennifer J et al. — PEC innovation (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42305635/
- 4.
From CFTR genotype enrichment to functional and longitudinal endotyping in Bronchiectasis.
Tian Changping et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42212955/
- 5.
Correspondence: 'CFTR variants in bronchiectasis'.
Yang Yuanli — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41696981/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
Recruiting — Phase 1 — Sionna Therapeutics Inc.
https://clinicaltrials.gov/study/NCT07035990
- 2.
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
Recruiting — Phase 1 — Cystetic Medicines, Inc.
https://clinicaltrials.gov/study/NCT05802264
- 3.
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Recruiting — Phase 2 — CSL Behring
https://clinicaltrials.gov/study/NCT07048262
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Cystic Fibrosis
Cystic fibrosis is a genetic condition that causes thick, sticky mucus to build up in the lungs and digestive system. It affects breathing and digestion. Treatments have advanced significantly, and many people with CF now live into adulthood and beyond.
Most Recent Research
Advances in standards of care and the recent introduction of Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators have significantly improved the prognosis for individuals with cystic fibrosis (CF). Prevention of respiratory infections in children with cystic fibrosis (cwCF) remains a cornerstone of treatment. Health authorities recommend both mandatory and non-mandatory vaccinations. This retrospective study aims to analyze compliance with the free vaccination program for preventable respiratory diseases in cwCF. This retrospective study assessed compliance with mandatory (H. influenzae type B, Bordetella pertussis) and non-mandatory (S. pneumoniae, COVID-19, Influenza) vaccinations for preventable respiratory diseases in cwCF in regular follow-up at the Regional Reference Center of Tuscany. Regarding mandatory vaccination, 131 (98.5%) out of 133 cwCF were regularly vaccinated, showing good coverage for Haemophilus influenzae type b(Hib). Influenza vaccination coverage peaked during the COVID-19 pandemic, reaching 79.6% in 2020-2021, then declined in the post-pandemic period across all age groups. For pneumococcal vaccination, 97% of cwCF received a complete primary series. Regarding COVID-19 vaccination, 67 (50.3%) out of 133 cwCF received at least two doses; no patients under 7 y were vaccinated. Coverage for pneumococcal and Hib vaccines was excellent. Conversely, Influenza and COVID-19 vaccinations had coverage below the targets set by health authorities. Further studies are needed to understand parental reasons for non-compliance and to develop strategies to increase Influenza and COVID-19 vaccination coverage in this high-risk cohort.
Common Questions
What is Cystic Fibrosis?
Cystic fibrosis is a genetic condition that causes thick, sticky mucus to build up in the lungs and digestive system. It affects breathing and digestion. Treatments have advanced significantly, and many people with CF now live into adulthood and beyond.
How many clinical trials are available for Cystic Fibrosis?
RareWays currently indexes 1338 clinical trials for Cystic Fibrosis, of which 157 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Cystic Fibrosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Cystic Fibrosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.